These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 34508258)

  • 1. The MYC oncogene - the grand orchestrator of cancer growth and immune evasion.
    Dhanasekaran R; Deutzmann A; Mahauad-Fernandez WD; Hansen AS; Gouw AM; Felsher DW
    Nat Rev Clin Oncol; 2022 Jan; 19(1):23-36. PubMed ID: 34508258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of MYC reverses tumorigenesis.
    Li Y; Casey SC; Felsher DW
    J Intern Med; 2014 Jul; 276(1):52-60. PubMed ID: 24645771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases.
    Sipos F; Firneisz G; Műzes G
    World J Gastroenterol; 2016 Sep; 22(35):7938-50. PubMed ID: 27672289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC activation is a hallmark of cancer initiation and maintenance.
    Gabay M; Li Y; Felsher DW
    Cold Spring Harb Perspect Med; 2014 Jun; 4(6):. PubMed ID: 24890832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC: Master Regulator of Immune Privilege.
    Casey SC; Baylot V; Felsher DW
    Trends Immunol; 2017 Apr; 38(4):298-305. PubMed ID: 28233639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.
    Bellovin DI; Das B; Felsher DW
    Adv Exp Med Biol; 2013; 734():91-107. PubMed ID: 23143977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-myc and c-Ha-ras cellular oncogenes and human papillomaviruses in benign and malignant cutaneous lesions.
    Pelisson I; Soler C; Pechoux C; Chignol MC; Viac J; Euvrard S; Chardonnet Y
    J Dermatol Sci; 1992 Jan; 3(1):56-67. PubMed ID: 1317208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response.
    Gorrini C; Squatrito M; Luise C; Syed N; Perna D; Wark L; Martinato F; Sardella D; Verrecchia A; Bennett S; Confalonieri S; Cesaroni M; Marchesi F; Gasco M; Scanziani E; Capra M; Mai S; Nuciforo P; Crook T; Lough J; Amati B
    Nature; 2007 Aug; 448(7157):1063-7. PubMed ID: 17728759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.
    Felsher DW
    Genes Cancer; 2010 Jun; 1(6):597-604. PubMed ID: 21037952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.
    Tran PT; Fan AC; Bendapudi PK; Koh S; Komatsubara K; Chen J; Horng G; Bellovin DI; Giuriato S; Wang CS; Whitsett JA; Felsher DW
    PLoS One; 2008 May; 3(5):e2125. PubMed ID: 18461184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC, metabolism, cell growth, and tumorigenesis.
    Dang CV
    Cold Spring Harb Perspect Med; 2013 Aug; 3(8):. PubMed ID: 23906881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
    Schaub FX; Dhankani V; Berger AC; Trivedi M; Richardson AB; Shaw R; Zhao W; Zhang X; Ventura A; Liu Y; Ayer DE; Hurlin PJ; Cherniack AD; Eisenman RN; Bernard B; Grandori C;
    Cell Syst; 2018 Mar; 6(3):282-300.e2. PubMed ID: 29596783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MYC oncogene is a global regulator of the immune response.
    Casey SC; Baylot V; Felsher DW
    Blood; 2018 May; 131(18):2007-2015. PubMed ID: 29514782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC Analysis in Cancer and Evolution.
    Hartl M; Bister K
    Methods Mol Biol; 2021; 2318():87-117. PubMed ID: 34019288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages.
    Dhanasekaran R; Hansen AS; Park J; Lemaitre L; Lai I; Adeniji N; Kuruvilla S; Suresh A; Zhang J; Swamy V; Felsher DW
    Cancer Res; 2023 Feb; 83(4):626-640. PubMed ID: 36525476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategies to inhibit MYC.
    McKeown MR; Bradner JE
    Cold Spring Harb Perspect Med; 2014 Oct; 4(10):. PubMed ID: 25274755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis.
    Pelengaris S; Abouna S; Cheung L; Ifandi V; Zervou S; Khan M
    BMC Biol; 2004 Dec; 2():26. PubMed ID: 15613240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The new role for an old guy: MYC as an immunoplayer.
    Marinkovic D; Marinkovic T
    J Cell Physiol; 2021 May; 236(5):3234-3243. PubMed ID: 33094851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noncanonical roles of the immune system in eliciting oncogene addiction.
    Casey SC; Bellovin DI; Felsher DW
    Curr Opin Immunol; 2013 Apr; 25(2):246-58. PubMed ID: 23571026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
    Hsu TY; Simon LM; Neill NJ; Marcotte R; Sayad A; Bland CS; Echeverria GV; Sun T; Kurley SJ; Tyagi S; Karlin KL; Dominguez-Vidaña R; Hartman JD; Renwick A; Scorsone K; Bernardi RJ; Skinner SO; Jain A; Orellana M; Lagisetti C; Golding I; Jung SY; Neilson JR; Zhang XH; Cooper TA; Webb TR; Neel BG; Shaw CA; Westbrook TF
    Nature; 2015 Sep; 525(7569):384-8. PubMed ID: 26331541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.